Acutus Medical, Inc. AFIB
We take great care to ensure that the data presented and summarized in this overview for Acutus Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AFIB
View all-
Deerfield Management Company, L.P. (Series C) New York, NY2.66MShares$106,4320.01% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.65MShares$105,9350.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny348KShares$13,9120.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA278KShares$11,1280.0% of portfolio
-
Black Rock Inc. New York, NY207KShares$8,2670.0% of portfolio
-
Geode Capital Management, LLC Boston, MA207KShares$8,2640.0% of portfolio
-
Two Sigma Securities, LLC New York, NY78.5KShares$3,1400.0% of portfolio
-
Virtu Financial LLC New York, NY75KShares$3,0010.0% of portfolio
-
State Street Corp Boston, MA51.9KShares$2,0740.0% of portfolio
-
Northern Trust Corp Chicago, IL35KShares$1,4010.0% of portfolio
Latest Institutional Activity in AFIB
Top Purchases
Top Sells
About AFIB
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company's product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Insider Transactions at AFIB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2024
|
Takeo Mukai CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,475
-10.42%
|
$0
$0.21 P/Share
|
|
Feb 06
2024
|
Tom Sohn SVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
7,582
-6.73%
|
$0
$0.17 P/Share
|
|
Feb 01
2024
|
Tom Sohn SVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,709
-4.83%
|
$0
$0.19 P/Share
|
|
Feb 01
2024
|
Takeo Mukai CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,869
-3.41%
|
$0
$0.19 P/Share
|
|
Jan 07
2024
|
David Roman President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,086
-6.76%
|
$0
$0.19 P/Share
|
|
Jan 07
2024
|
Kevin Mathews SVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
6,342
-9.4%
|
$0
$0.19 P/Share
|
|
Sep 01
2023
|
Takeo Mukai CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,729
-2.01%
|
$0
$0.49 P/Share
|
|
Aug 05
2023
|
Kevin Mathews SVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
134
-0.2%
|
$0
$0.69 P/Share
|
|
Aug 05
2023
|
Tom Sohn SVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-0.36%
|
$0
$0.69 P/Share
|
|
Aug 02
2023
|
Takeo Mukai CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
501
-0.6%
|
-
|
|
Aug 01
2023
|
David Roman President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,484
-1.79%
|
-
|
|
Aug 01
2023
|
Tom Sohn SVP, Gen. Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+14.42%
|
-
|
|
Jun 15
2023
|
James E Flynn Director |
BUY
Grant, award, or other acquisition
|
Indirect |
8,400
+28.75%
|
-
|
|
Jun 15
2023
|
Niamh Louise Pellegrini Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+28.6%
|
-
|
|
Jun 15
2023
|
Jason K Garland Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+27.27%
|
-
|
|
Jun 15
2023
|
Andrew El Bardissi Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+28.75%
|
-
|
|
Jun 15
2023
|
R Scott Huennekens Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,920
+33.33%
|
-
|
|
Jun 15
2023
|
David P Bonita Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+28.75%
|
-
|
|
Jun 15
2023
|
John F Sheridan Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+25.65%
|
-
|
|
Jun 15
2023
|
Shaden Marzouk Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+28.75%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 89.7K shares |
|---|
| Payment of exercise price or tax liability | 81.6K shares |
|---|